3 Latin America Generics, Custom Synthesis Ingredients and Finished Dosages Stocks With a Strong Future Roadmap: Caplin Point Laboratories, Divi's Laboratories and Granules India

Emerging market and API pharma stocks give investors exposure to companies that serve fast-growing markets and global ingredient buyers. Caplin Point Laboratories, Divi's Laboratories and Granules India cover Latin America branded generics, custom synthesis ingredients and finished dosages.

This list covers three emerging market and API pharma stocks with complete current figures: Caplin Point Laboratories, Divi's Laboratories and Granules India. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Emerging Market and API Pharma Stocks?

Emerging market and API pharma stocks are listed companies that sell branded generics in developing markets or supply active ingredients and finished dosages to global customers. Their earnings depend on volume growth, long-term contracts and plant capacity.

Emerging Market and API Pharma Stocks at a Glance

On valuation, Caplin Point Laboratories and Granules India trade at a P/E below the industry P/E, while Divi's Laboratories trades above it, which reflects the growth the market already expects. Readers comparing emerging market and API pharma stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in emerging market and API pharma stocks can use the coming numbers to test whether growth is holding.

Why Do Emerging Market and API Pharma Stocks Have a Strong Roadmap in India?

Emerging market and API pharma stocks have a strong roadmap in India because developing economies are spending more on medicines, and global drug makers are sourcing more ingredients from Indian plants.

• Rising medicine use. Higher incomes in emerging markets lift demand for branded generics.
• Contract manufacturing. Long-term supply deals give visibility to ingredient makers.
• Finished dosages. Moving up from ingredients to formulations improves margins.

Why Caplin Point Laboratories Features Among These Emerging Market and API Pharma Stocks

Among the emerging market and API pharma stocks on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.

In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%.

Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.

Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

What to watch: Follow new US product approvals and currency trends in Latin American markets.

Why Divi's Laboratories Features Among These Emerging Market and API Pharma Stocks

Among the Latin America branded generic shares on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Granules India Features Among These Emerging Market and API Pharma Stocks

Among the three companies on this list, Granules India is a Hyderabad-based pharmaceutical manufacturer that makes active ingredients, intermediates and finished dosage forms, with a strong position in paracetamol, metformin and ibuprofen.

Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%.

In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0.

Roadmap: The company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What to watch: Monitor new product approvals and the share of finished dosages in total sales.

Caplin Point Laboratories vs Divi's Laboratories vs Granules India on Key Financials

The table below sets the three emerging market and API pharma stocks side by side on revenue, profit and margin, using reported figures.

Caplin Point Laboratories posts the highest return on equity in this group at 17.9%. Divi's Laboratories has the largest FY26 revenue at Rs 11,067 crore, and Caplin Point Laboratories shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with emerging market and API pharma stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several custom synthesis ingredient stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Emerging Market and API Pharma Stocks

Every theme carries risks that deserve a check before any decision. For these emerging market and API pharma stocks, the main points are: Long-term Latin America branded generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Currency swings. Exchange rate moves can affect reported revenue in overseas markets.
• Customer concentration. A few large customers can shape quarterly revenue.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter emerging market and API pharma stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Emerging Market and API Pharma Stocks

Emerging market and API pharma stocks reward investors who follow volumes, contracts and plant capacity together. Caplin Point Laboratories, Divi's Laboratories and Granules India each follow a different growth route. Based on the 21 October 2026 close, Caplin Point Laboratories trades at Rs 2,221.6, Divi's Laboratories at Rs 9,190 and Granules India at Rs 807.65. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these emerging market and API pharma stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track emerging market and API pharma stocks, set price alerts and get research-backed stock ideas.

What are emerging market and API pharma stocks?

Ans. Emerging market and API pharma stocks are listed companies that sell branded generics in developing markets or supply active ingredients and finished dosages to global customers. Their earnings depend on volume growth, long-term contracts and plant capacity. This list looks at three of them, Caplin Point Laboratories, Divi's Laboratories and Granules India, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.

Which emerging market and API pharma stocks are covered in this list?

Ans. This list covers Caplin Point Laboratories, Divi's Laboratories and Granules India. Based on the 21 October 2026 close, Caplin Point Laboratories traded at Rs 2,221.6, Divi's Laboratories at Rs 9,190 and Granules India at Rs 807.65. Their return on equity ranges from 11.7% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 15.2%.

Why do emerging market and API pharma stocks have a strong future roadmap in India?

Ans. Emerging market and API pharma stocks have a strong roadmap in India because developing economies are spending more on medicines, and global drug makers are sourcing more ingredients from Indian plants. The main drivers are as follows. Rising medicine use. Higher incomes in emerging markets lift demand for branded generics. Contract manufacturing. Long-term supply deals give visibility to ingredient makers. Finished dosages. Moving up from ingredients to formulations improves margins. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Caplin Point Laboratories performed financially?

Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Granules India performed financially?

Ans. Revenue rose from Rs 3,783 crore in FY22 to Rs 5,386 crore in FY26, a compound annual growth rate of 9.2%. Net profit grew from Rs 413 crore in FY22 to Rs 595 crore in FY26, which works out to a compound annual growth rate of 9.6%. In the June 2026 quarter, revenue grew 20.6% year on year to Rs 1,479 crore, while net profit rose 59.8% to Rs 180 crore. The company has a return on equity of 11.7%, a debt to equity ratio of 0.30 and a market capitalisation of Rs 22,002 crore. The stock trades at a P/E of 33.2, below the industry P/E of 36.0. Looking ahead, the company is shifting its mix towards finished dosages, which earn better margins than ingredients, and it supplies customers in regulated markets, especially the United States. Capacity additions and new product approvals support steady growth.

What risks should investors check before buying emerging market and API pharma stocks?

Ans. Investors should check a few risks before buying emerging market and API pharma stocks. Currency swings. Exchange rate moves can affect reported revenue in overseas markets. Customer concentration. A few large customers can shape quarterly revenue. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of emerging market and API pharma stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.